Cryoport, Inc. (NASDAQ:CYRX) Short Interest Update

Cryoport, Inc. (NASDAQ:CYRX) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 2,080,000 shares, a decrease of 5.5% from the December 15th total of 2,200,000 shares. Approximately 4.4% of the company’s shares are sold short. Based on an average daily volume of 405,400 shares, the days-to-cover ratio is currently 5.1 days.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the sale, the chief executive officer now owns 731,897 shares in the company, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the transaction, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cryoport

A number of hedge funds have recently bought and sold shares of CYRX. SG Americas Securities LLC increased its stake in shares of Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock worth $1,142,000 after buying an additional 45,430 shares during the period. Avanza Fonder AB purchased a new stake in shares of Cryoport in the 4th quarter valued at approximately $64,000. NRI Wealth Management LC acquired a new stake in shares of Cryoport in the 4th quarter valued at $149,000. JPMorgan Chase & Co. lifted its position in shares of Cryoport by 1,464.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company’s stock worth $2,475,000 after purchasing an additional 285,726 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Cryoport by 5.5% during the third quarter. Franklin Resources Inc. now owns 385,619 shares of the company’s stock worth $3,127,000 after purchasing an additional 20,077 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Stock Up 0.1 %

Cryoport stock opened at $7.50 on Monday. The firm has a market capitalization of $370.73 million, a P/E ratio of -2.22 and a beta of 1.58. The stock’s fifty day simple moving average is $7.68 and its 200-day simple moving average is $7.88. Cryoport has a twelve month low of $5.32 and a twelve month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Friday. Roth Mkm lowered their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 8th. UBS Group boosted their target price on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th. Finally, Guggenheim initiated coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.29.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.